Eli Lilly (LLY) said it “has no affiliation with Mangoceuticals. Any communication or media report suggesting a partnership between Lilly and Mangoceuticals is false. In fact, Lilly sued Mangoceuticals last year and obtained a permanent injunction. While Lilly has no affiliation or partnership with Mangoceuticals, any healthcare provider-including those who work with telehealth platforms-can prescribe Lilly medicines and send valid, on-label prescriptions for Zepbound (tirzepatide) single-dose vials directly to LillyDirect Self Pay Pharmacy Solutions for fulfillment.” This follows Mangoceuticals (MGRX) announcement that it had launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound from Eli Lilly and Wegovy from Novo Nordisk (NVO). Shares of Mangoceuticals are sliding more than 16% in afternoon trading.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Hims & Hers Stock (HIMS) Plunges despite New ‘Affordable’ Healthcare Platform
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Pfizer Stock (PFE) Rises as Metsera Shareholders Approve $10B Acquisition
- Eli Lilly Stock Gets New Street-High Price Target – Citi Says Oral Weight-Loss Drug Sales Potential Is Underestimated
- Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls